Therapeutic Perspectives of Drugs Targeting Toll-Like Receptors Based on Immune Physiopathology Theory of Alzheimers Disease

Author(s): Andrew R. Schneider, Youssef Sari

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 13 , Issue 5 , 2014

Become EABM
Become Reviewer


Alzheimer’s disease (AD) is a neurodegenerative disease associated with the development of dementia. It has been established that the pathological hallmarks of neurofibrillary tau protein tangles and senile β-amyloid protein plaques lead to degeneration of neurons via inflammatory pathways. The progressive death of neurons, primarily cholinergic, results in a gradual and fatal decline of cognitive abilities and memory. By targeting these pathological hallmarks and their associated pathways, AD drug therapy can potentially attenuate the disease state. In this review article, we focus on newly proposed and experimental AD drug treatment. We discuss three characteristic areas of AD treatment: prevention of neurotoxic β-amyloid protein plaque formation, stability of neuronal tau proteins, and increase in neuronal growth and function. The primary drug therapy methods and patents discussed include the use of neurotrophic factors and targeting of the amyloid precursor protein cleavage pathway as prevention of β-amyloid formation and tau aggregation.

Keywords: Alzheimer's disease, β-amyloid, neurotrophic factors, colivelin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [909 - 920]
Pages: 12
DOI: 10.2174/1871527313666140711093858
Price: $65

Article Metrics

PDF: 28